Geometriae Dedicata

Springer Nature

Springer Nature

ISSN: 00465755, 15729168

Cobalt

Journal publications in Cobalt

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Login with ORCID

SCImago

Q3

WOS

Q3

Impact factor

0.5

SJR

0.452

CiteScore

0.9

Categories

Geometry and Topology

Areas

Mathematics

Years of issue

1972-2025

journal names

Geometriae Dedicata

journal website

All time from 2020

Publications

4 597

Citations

29 445

h-index

56

Top-3 citing journals

Geometriae Dedicata

Geometriae Dedicata (1254 citations)

Journal of Algebra

Journal of Algebra (697 citations)

Journal of Geometry

Journal of Geometry (614 citations)

Top-3 organizations

All time in 5 years

Ghent University

Ghent University (53 publications)

University of Illinois Urbana-Champaign

University of Illinois Urbana-Champaign (49 publications)

Kiel University

Kiel University (47 publications)

Top-3 countries

All time in 5 years

USA (1328 publications)

Germany (800 publications)

France (324 publications)

USA (122 publications)

Germany (51 publications)

China (46 publications)

Most cited in 5 years

Found

Publication title from chars

Since

For

Clear filter

Publications found: 747

Q2

Taylor & Francis

Detailed investigation of the levodopa response rates in distinct motor subscores in Parkinson’s disease patients with and without STN-DBS

Onder H., Oksuz M., Comoglu S.

Q2

Taylor & Francis

Neurodegenerative disease management , 2025 , citations by CoLab: 0

Q2

Taylor & Francis

Correction

Q2

Taylor & Francis

Neurodegenerative disease management , 2025 , citations by CoLab: 0

Q2

Taylor & Francis

Economic evaluation of mHealth solutions in PD: where do we stand?

Kanellos F.S., Petkou E., Konitsiotis S., Simos Y.V., Lakkas L., Peschos D., Tsamis K.I.

Q2

Taylor & Francis

Neurodegenerative disease management , 2025 , citations by CoLab: 0

Q2

Taylor & Francis

Advances in the management of Alzheimer’s disease

Faheem M.S., Khan A.A., Nawaz M.

Q2

Taylor & Francis

Neurodegenerative disease management , 2025 , citations by CoLab: 0

Q2

Taylor & Francis

A plain language summary of a study exploring the experiences of people with relapsing–remitting multiple sclerosis: what symptoms and impacts of the disease matter most and how can they be evaluated better?

Barrett A., Olayinka-Amao O., Ziemssen T., Bharadia T., Henke C., Kamudoni P.

Q2

Taylor & Francis

Neurodegenerative disease management , 2025 , citations by CoLab: 0

Q2

Taylor & Francis

Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice

Amin M., Harvey T., Pineda D.M., Tai M., Shao Q., Brown B., Gadkari A., Moss B., Conway D.S., Hersh C.M.

Q2

Taylor & Francis

Neurodegenerative disease management , 2025 , citations by CoLab: 0

Q2

Taylor & Francis

Friedreich ataxia: what can we learn from non-GAA repeat mutations?

Lynch D.R., Shen M., Wilson R.B.

Q2

Taylor & Francis

Neurodegenerative disease management , 2025 , citations by CoLab: 0

Q2

Taylor & Francis

Gut microbiota and multiple sclerosis: a potential diagnostic and prognostic marker?

Zoledziewska M., Lorefice L.

Q2

Taylor & Francis

Neurodegenerative disease management , 2024 , citations by CoLab: 0

Q2

Taylor & Francis

Neurofilament light chain: a biomarker at the crossroads of clarity and confusion for gene-directed therapies

A Virata M.C., Catahay J.A., Lippi G., Henry B.M.

Q2

Taylor & Francis

Neurodegenerative disease management , 2024 , citations by CoLab: 0

Q2

Taylor & Francis

An interdisciplinary approach to rehabilitation in Parkinson's disease: case series

Lowell E.R., Macpherson C., Villarreal-Cavazos K., Chandrana A., Sevitz J.S., Veit K., Dakin A., Quinn L., Troche M.S.

Q2

Taylor & Francis

Neurodegenerative disease management , 2024 , citations by CoLab: 0

Q2

Taylor & Francis

Effectiveness of neuro-feedback on Alzheimer’s rehabilitation: a bibliometric analysis

Verma S., Kurdekar A.

Q2

Taylor & Francis

Neurodegenerative disease management , 2024 , citations by CoLab: 0

Q2

Taylor & Francis

Biological activities of astaxanthin in the treatment of neurodegenerative diseases

Lotfi A., Abroodi Z., Khazaei M.

Q2

Taylor & Francis

Neurodegenerative disease management , 2024 , citations by CoLab: 1

Q2

Taylor & Francis

Improvements in quality of life of people with relapsing multiple sclerosis treated with cladribine tablets during the 2-year CLARIFY-MS study: a plain language summary

Brochet B., Solari A., Lechner-Scott J., Piehl F., Langdon D., Hupperts R., Selmaj K., Patti F., Brieva L., Maidal E.M., Alexandri N., Smyk A., Nolting A., Montalban X., Kubala Havrdova E.

Q2

Taylor & Francis

Neurodegenerative disease management , 2024 , citations by CoLab: 0

Q2

Taylor & Francis

Mapping the journey of patients and care partners living with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia: developing a framework for improvements in care

Rutherford H.A., Rush B.K., Smith A., Sullivan E., Martinez-Rubio C., Toumadj A., Piana R.L., Cassandro C.

Q2

Taylor & Francis

Neurodegenerative disease management , 2024 , citations by CoLab: 0

Q2

Taylor & Francis

Benefits of self-paced concurrent training on lung function, cardiopulmonary fitness and fatigue perception in patients with multiple sclerosis

Jallouli S., Maaloul R., Ghroubi S., Kammoun R., Damak M., Sakka S., Driss T., Marco G.D., Mhiri C., Elleuch M.H., Feki W., Hammouda O.

Q2

Taylor & Francis

Neurodegenerative disease management , 2024 , citations by CoLab: 0

1
2
3
...
4
...
50